Complement component C3d-antigen complexes can either augment or inhibit B lymphocyte activation and humoral immunity in mice depending on the degree of CD21/CD19 complex engagement

被引:41
作者
Lee, Y
Haas, KM
Gor, DO
Ding, XD
Karp, DR
Greenspan, NS
Poe, JC
Tedder, TF
机构
[1] Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA
[2] Case Western Reserve Univ, Sch Med, Inst Pathol, Cleveland, OH 44106 USA
[3] Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA
关键词
D O I
10.4049/jimmunol.175.12.8011
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
C3d can function as a molecular adjuvant by binding CD21 and thereby enhancing B cell activation and humoral immune responses. However, recent studies suggest both positive and negative roles for C3d and the CD19/CD21 signaling complex in regulating humoral immunity. To address whether signaling through the CD19/CD21 complex can negatively regulate B cell function when engaged by physiological ligands, diphtheria toxin (DT)-C3d fusion protein and C3dg-streptavidin (SA) complexes,were used to assess the role of CD21 during BCR-induced activation and in vivo immune responses. Immunization of mice with DT-C3d(3), significantly reduced DT-specific Ab responses independently of CD21 expression or signaling. By contrast, SA-C3dg tetramers dramatically enhanced anti-SA responses when used at low doses, whereas 10-fold higher doses did not augment immune responses, except in CD21/35-deficient mice. Likewise, SA-C3dg (1 mu g/ml) dramatically enhanced BCR-induced intracellular calcium concentration ([Ca2+] (i)) responses in vitro, but had no effect or inhibited [Ca2+](i) responses when used at 10- to 50-fold higher concentrations. SA-C3dg enhancement of BCR-induced [Ca2+](i) responses required CD21 and CD19 expression and resulted in significantly enhanced CD19 and Lyn phosphorylation, with enhanced Lyn/CD19 associations. BCR-induced CD22 phosphorylation and Src homology 2 domain-containing protein tyrosine phosphatase-1/CD22 associations were also reduced, suggesting abrogation of negative regulatory signaling. By contrast, CD19/CD21 ligation using higher concentrations of SA-C3dg significantly inhibited BCR-induced [Ca2+](i) responses and inhibited CD19, Lyn, CD22, and Syk phosphorylation. Therefore, C3d may enhance or inhibit Ag-specific humoral immune responses through both CD21-dependent and -independent mechanisms depending on the concentration and nature of the Ag-C3d complexes.
引用
收藏
页码:8011 / 8023
页数:13
相关论文
共 71 条
[1]   Disruption of the Cr2 locus results in a reduction in B-1a cells and in an impaired B cell response to T-dependent antigen [J].
Ahearn, JM ;
Fischer, MB ;
Croix, D ;
Goerg, S ;
Ma, MH ;
Xia, JR ;
Zhou, XN ;
Howard, RG ;
Rothstein, TL ;
Carroll, MC .
IMMUNITY, 1996, 4 (03) :251-262
[2]   SIGNALING THROUGH CD19, FC-RECEPTORS OR TRANSFORMING GROWTH-FACTOR-BETA - EACH INHIBITS THE ACTIVATION OF RESTING HUMAN B-CELLS DIFFERENTLY [J].
BARRETT, TB ;
SHU, GL ;
DRAVES, KE ;
PEZZUTTO, A ;
CLARK, EA .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1990, 20 (05) :1053-1059
[3]   POSTSECRETORY MODIFICATIONS OF STREPTAVIDIN [J].
BAYER, EA ;
BENHUR, H ;
HILLER, Y ;
WILCHEK, M .
BIOCHEMICAL JOURNAL, 1989, 259 (02) :369-376
[4]   SYK is upstream of phosphoinositide 3-kinase in B cell receptor signaling [J].
Beitz, LO ;
Fruman, DA ;
Kurosaki, T ;
Cantley, LC ;
Scharenberg, AM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (46) :32662-32666
[5]   Was it there all the time? [J].
Bennett, M ;
Leanderson, T .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2003, 57 (06) :499-505
[6]   C3d binding to the circumsporozoite protein carboxy-terminus deviates immunity against malaria [J].
Bergmann-Leitner, ES ;
Scheiblhofer, S ;
Duncan, EH ;
Leitner, WW ;
Chen, D ;
Angov, E ;
Khan, F ;
Williams, JL ;
Winter, DB ;
Thalhamer, J ;
Lyon, JA ;
Tsokos, GC .
INTERNATIONAL IMMUNOLOGY, 2005, 17 (03) :245-255
[7]   Cr2, a candidate gene in the murine Sle1c lupus susceptibility locus, encodes a dysfunctional protein [J].
Boackle, SA ;
Holers, VM ;
Chen, XJ ;
Szakonyi, G ;
Karp, DR ;
Wakeland, EK ;
Morel, L .
IMMUNITY, 2001, 15 (05) :775-785
[8]  
Botto M, 1993, Int Rev Immunol, V10, P37, DOI 10.3109/08830189309051170
[9]  
BRADBURY LE, 1992, J IMMUNOL, V149, P2841
[10]  
CALLARD RE, 1992, J IMMUNOL, V148, P2983